Zuellig Pharma Corporation

Zuellig Pharma Corporation, a Pharmaceutical Preparation Manufacturing company based in PH, reported its 2021 Scope 3 emissions at approximately 182,171,000 kg CO2e. This includes about 10,898,000 kg CO2e from capital goods, 6,693,000 kg CO2e from business travel, 5,058,000 kg CO2e from employee commute, 17,332,000 kg CO2e from purchased goods and services, 1,614,000 kg CO2e from waste generated in operations, 14,692,000 kg CO2e from fuel and energy related activities, and 108,342,000 kg CO2e from upstream transportation and distribution. Scope 1 and Scope 2 emissions data were not disclosed for 2021.

Zuellig Pharma Corporation has set ambitious climate commitments, with Science Based Targets initiative (SBTi) validated targets. They are committed to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030 from a 2021 base year. Additionally, they aim to reduce absolute Scope 3 GHG emissions from fuel and energy related activities, upstream transportation and distribution, and waste generated in operations by 25% within the same timeframe. Long-term, Zuellig Pharma Corporation commits to reaching net-zero greenhouse gas emissions across the entire value chain by 2045. This includes a 90% reduction in absolute Scope 1 and 2 GHG emissions by 2045 from a 2021 base year, and a 90% reduction in absolute Scope 3 emissions from purchased goods and services, capital goods, fuel- and energy-related activities, upstream transportation and distribution, and waste generated from operations within the same period.

The company also aims to be carbon neutral for its own operations by 2030, with a mid-term target of a 35% reduction by 2025. These targets are consistent with reductions required to keep global warming to 1.5°C. Zuellig Pharma Corporation's climate initiatives are cascaded from the parent company, Zuellig Pharma Corporation.